Search

everythinglearnresearchcommunity

for

Search:↓

A genetic marker linked to a type of hair loss was found in most patients studied.

Frontal Fibrosing Alopecia is a hair loss condition mainly affecting postmenopausal women, with unclear causes and various clinical patterns.

Frontal fibrosing alopecia is linked to four genetic areas, especially the HLA-B*07:02 allele.

Certain genetic variants are linked to frontal fibrosing alopecia in Spanish patients.

Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.

Women with excessive hair growth or polycystic ovary disease may more often carry a gene variant for 21 hydroxylase deficiency.

The cause of Frontal fibrosing alopecia, a type of hair loss, is complex, likely involving immune responses and genetics, but is not fully understood.

Oral contraceptive use may increase the risk of frontal fibrosing alopecia in women with a specific CYP1B1 gene variant.

Men generally have more severe COVID-19 cases and higher death rates than women due to biological differences.

Alopecia areata is linked to thyroid autoimmunity but not type 1 diabetes.

Alopecia areata causes hair loss due to an immune attack on hair follicles, influenced by genetics and environment.

The study concluded that testing hormone levels after stimulation is not reliable for identifying carriers of 21-hydroxylase deficiency; genetic testing is necessary.

Psoriasis patients' immune response to a hair protein depends on their specific gene type.

A gluten-free diet significantly improves skin and health issues in people with dermatitis herpetiformis, a skin condition linked to celiac disease.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

Certain genetic variants linked to immune response increase the risk of alopecia areata in Taiwanese people.

The hepatitis B vaccine did not cause hair loss in the tested mice.

Botulinum toxin type A significantly reduces scalp psoriasis severity compared to placebo.

Certain HLA class II alleles increase or decrease the risk of alopecia areata.

APS-1 in Italy shows diverse AIRE mutations and various autoimmune issues.

StemMACS media is better for growing therapeutic stem cells than PowerStem media.

Vogt-Koyanagi-Harada disease affects vision and skin, mainly in people with darker skin, and is treated with steroids and immunosuppressants.

Mercury allergy linked to specific genes may contribute to burning mouth syndrome, and silicon might play a role in maintaining healthy hair.

Half of people with Alopecia Areata may see hair regrowth within a year without treatment, but recovery is unpredictable.

Down Syndrome patients with Alopecia Areata often have hypothyroidism and specific immune abnormalities.

Patients with Alopecia areata have fewer specific immune cells that normally regulate the immune system, which may contribute to the condition.

Genetic factors, skin barrier, immune function, and obesity influence risk of fungal skin infections.

Dexamethasone-primed stem cell media shows promise in treating lupus by reducing symptoms and inflammation.

Graft-versus-host disease is a complication where donor immune cells attack the recipient's body, often affecting the skin, liver, and gastrointestinal tract.

Transplanting growing hair follicles into scars can help regenerate and improve scar tissue.